Petefészekrák: vizsgálatok itt: Portugália
10 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 10.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Where
- Coimbrã, Lisbon, Porto
- Életkor
- 18 év and over
- People
- 420 worldwide
- Run by
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT07546500 - 1/2. fázisTaking peopleA Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Where
- Braga, Lisbon
- Életkor
- 18 év and over
- People
- 248 worldwide
- Run by
- Terremoto Biosciences Inc.
See details and how to joinNCT07109726 - 2/3. fázisTaking peopleA Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Where
- Amadora, Lisbon, Porto
- Életkor
- 18 év and over
- People
- 860 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06161025 · EU 2023-507914-28-00 - 1/2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Lisbon, Porto
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Where
- Lisbon, Porto
- Életkor
- 18 év and over
- People
- 770 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06824467 · EU 2023-508015-23-00 - 1. fázisTaking peopleA Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
- Where
- Lisbon, Porto
- Életkor
- 18 év and over
- People
- 285 worldwide
- Run by
- AbbVie
See details and how to joinNCT07278336 · EU 2025-522209-40-00 - No phaseTaking peopleInnovative Ovarian Cancer Biomarker Assays
- Where
- Lisbon
- Életkor
- 35 év and over
- People
- 2080 worldwide
- Run by
- National and Kapodistrian University of Athens
See details and how to joinNCT07693894 - 1. fázisTaking peopleDrug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Where
- Lisbon
- Életkor
- 18 év and over
- People
- 32 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07402915 · EU 2025-522731-34-00 - No phaseTaking peopleCanRisk-Based Ovarian Cancer Risk Assessment Versus Standard Practice (DISARM CSA)
- Where
- Lisbon
- Életkor
- 18 év to 75 év
- People
- 2130 worldwide
- Run by
- Instituto Portugues Oncologia de Lisboa Francisco Gentil
See details and how to joinNCT07809659 - 4. fázisTaking peoplezAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric randomized clinical study with intervention
- Where
- Coimbra, Lisbon, Porto
- Életkor
- 18 év and over
- People
- 276
- Run by
- Rita Fior
See details and how to join2023-509598-22-01 · EU 2023-509598-22-01